Estimating the value of sodium‐glucose cotransporter‐2 inhibitors within the context of contemporary guidelines and the totality of evidence
Authors' conclusion
Our results show that SGLT2 inhibitors have the potential to lower healthcare costs while improving health outcomes in eligible patient subpopulations.
Study context
- Population
- Eligible T2D subpopulations at established clinical review/intensification points
- Comparison
- SGLT2i pathways per NICE NG28-2022 guidelines vs NG28-2015 guidelines
- Outcome
- Cost-effectiveness: incremental cost-effectiveness ratio lifetime trajectories and timepoints for complete cost-offset
- Follow-up
- Lifetime
Methodological detailsmodelling study, Cardiff type 2 diabetes model, lifetime horizon, costs discounted at 3.5%
- Modelling study
- Cardiff type 2 diabetes model
- Lifetime horizon
- Costs discounted at 3.5%
Main finding
As reported in the abstract
Cost-effectiveness of SGLT2i introduction
SGLT2i introduction cost-effective for all subpopulations on NG28-2022 pathways; cost-saving after (years post-initiation)
2 and 16
Incremental QALY gains (range), resulting in dominance for NG28-2022 in all scenarios
0.58-1.12
Original publication
Estimating the value of sodium‐glucose cotransporter‐2 inhibitors within the context of contemporary guidelines and the totality of evidence. Diabetes Obes Metab. Published 29 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →